Despite universal germline testing recommended for some cancers, this SEER analysis of patients treated in California and Georgia from 2013 to 2019 reports penetration of testing surpassed 50% only for male breast cancers, approached 50% for ovarian cancer and reached 20% for pancreatic cancer. | Kurian, JAMA 2023
